Trailing-twelve-month (TTM) revenue is $317.16 Million with a year-over-year growth of +39.02%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $62,550,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $72,376,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $90,096,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $92,142,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $317,164,000 |
Current P/S: $2,202,767,174 market capitalization ÷ $317,164,000 TTM revenue = 6.95x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:35:11.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $92.14M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:36:56.092Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Agility | $11M | $13M | $15M | $18M | $21M | $24M |
| Dds | $42M | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CANADA | N/A | $6M | $6M | $7M | $9M | $12M |
| NETHERLANDS | N/A | $7M | $7M | $7M |
$317.16M
$317.16 Million
+39.02%
vs. $228.14M a year ago (TTM)
+38.23%
5 Year compound annual growth rate
1 Year
+39.02%
3 Year
+60.76%
5 Year
+38.23%
10 Year
+17.73%
15 Year
+11.54%
20 Year
+10.80%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $251.66M | +$81.20M | +47.64% |
| 2024 | $170.46M | +$83.69M | +96.44% |
| 2023 | $86.78M | +$7.77M | +9.84% |
| 2022 | $79.00M | +$9.25M | +13.25% |
| 2021 | $69.75M | +$11.52M | +19.77% |
| 2020 |
TTM Growth
+39.02%
3-Year CAGR
+60.76%
5-Year CAGR
+38.23%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:36:56.092Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| DDS | N/A | $53M | $57M | $62M | $141M | $221M |
|---|
| Synodex | N/A | $4M | $7M | $8M | $8M | $7M |
|---|
| Synodex Member | $5M | N/A | N/A | N/A | N/A | N/A |
|---|
| $8M |
| $9M |
| Other - Principally Europe | $8M | $7M | $7M | $7M | $10M | N/A |
|---|
| UNITED KINGDOM | N/A | $12M | $11M | $11M | $10M | $10M |
|---|
| UNITED STATES | N/A | $38M | $49M | $54M | $134M | $212M |
|---|
| $58.24M |
| +$2.38M |
| +4.26% |
| 2019 | $55.86M | ($1.56M) | (2.72%) |
| 2018 | $57.42M | ($3.51M) | (5.76%) |
| 2017 | $60.93M | ($2.15M) | (3.40%) |
| 2016 | $63.07M | +$4.55M | +7.78% |
